Tweet
ByJosh Nathan-Kazis
Aug. 31, 2021 10:46 am ET
...
The company’s monoclonal antibody treatment for Covid-19, which it markets under the name REGEN-COV, earned $2.6 billion in sales in the second quarter of the year, as the U.S. government made a purchase of more than 1 million doses. The federal government provides the drug for free in the U.S. It is authorized by the U.S. Food and Drug Administration to treat certain Covid-19 patients and, in some cases, to prevent infection in people who have been exposed to the virus.
In his note on Tuesday, Huseynov wrote that he expects a “major catalyst” related to REGEN-COV “within a month.”
Huseynov said that the federal government will either preorder another million doses of REGEN-COV for $2,100 per dose, or REGN could bring the drug to the commercial market, and charge between $3,000 and $5,000 per dose, according to Huseynov’s estimates....
Comment